PPARG and type 2 diabetes mellitus: PPARγ ligands glitazones (rosiglitazone and pioglitazone, Figure 1) are deemed as insulin sensitizer to improve the symptoms of patients with Type 2 diabetes mellitus (T2DM) [9].